MedTrace Logo

In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI

NCT03179449 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-04-14

No results posted yet for this study

Summary

This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a noninvasive imaging biomarker of inflammation.

Conditions

  • Childhood Brain Neoplasm

Interventions

DIAGNOSTIC_TEST

Diagnostic (ferumoxytol-enhanced MRI)

Undergo ferumoxytol-enhanced MRI

PROCEDURE

Surgery

Undergo surgical resection

DRUG

Ferumoxytol

Given IV

OTHER

Tissue Analysis

Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Michael Iv

    lead OTHER

Principal Investigators

  • Michael Iv · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2025-06-01
Completion
2025-06-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03179449 on ClinicalTrials.gov